Journal of Psychiatry

A rapid improvement in obsessive-compulsive disorder with Milnacipran in a schizophrenic patient

2^nd International Conference on Psychiatry and Psychiatric Disorders

May 02-04, 2016 Chicago, Illinois, USA

Shan Hung

Taipei City Hospital, Taiwan

Posters & Accepted Abstracts: J Psychiatry

Abstract:

One-fourth of schizophrenic patients suffer from co-morbid obsessive and compulsive symptoms (OCS), posing a considerable challenge for treatment. To avoid worsening the severity of obsessive-compulsive symptoms in schizophrenic patients, the use of mainly dopaminergic second-generation antipsychotics such as amisulpride and aripiprazole has been proposed. In addition, augmentation with a selective serotonin reuptake inhibitor (SSRI) was reported. However, a substantial portion of patients fail to respond to such an approach. It has been suggested that serotonin-norepinephrine reuptake inhibitors (SNRIs) have potential efficacy among SSRI-resistant OCD patients. Herein, we report a schizophrenic patient who, after being switched from escitalopram to milnacipran, showed a rapid improvement of his debilitating OCD. To our knowledge, this is the first report describing SNRI as treatment of the co-morbid OCD in schizophrenia. We discussed unique pharmacological property, and possibly multineurotransmitter pathway involving in the treatment of OCS among schizophrenic patients.

Biography :

Email: DXL09@tpech.gov.tw